Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of HSP90 inhibitor to inhibition of STAT3 mitochondrial transport and treatment of asthma

An inhibitor, mitochondrial technology, applied in the field of medicine, can solve problems such as asthma treatment reports that have not yet been reported, and achieve the effect of inhibiting inflammatory response and reducing side effects

Active Publication Date: 2022-04-01
TSINGHUA UNIV
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006]Currently, there is no report targeting the mitochondrial transport of STAT3 in the treatment of asthma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of HSP90 inhibitor to inhibition of STAT3 mitochondrial transport and treatment of asthma
  • New application of HSP90 inhibitor to inhibition of STAT3 mitochondrial transport and treatment of asthma
  • New application of HSP90 inhibitor to inhibition of STAT3 mitochondrial transport and treatment of asthma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] All experimental mice were of C57BL / 6 background and matched for sex and age (6-10 weeks old). All experimental mice were raised in SPF-grade rooms in the Experimental Animal Center of Tsinghua University, with a temperature of 22-26°C and a circadian rhythm of 12 / 12 hours. All operations were strictly complied with the national and Tsinghua University laboratory animal welfare rules and regulations, and the relevant regulations formulated by Tsinghua University Laboratory Animal Use and Management Committee (IACUC).

[0034] To establish an acute asthma model, mice were anesthetized with isoflurane gas, and then 20 μg of papain (both dissolved in 40 μl of 1×PBS) was given by nasal instillation. Mice were intranasally treated with papain on days 0, 1, and 3, and analyzed on day 4. For GA administration, first prepare 50 mM GA stock solution with DMSO, then dilute with 1×PBS, and treat mice with 4.5 μg GA (volume 40 μl) nasally from -1 to 3 days.

[0035] 1. Loss of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a novel application of an HSP90 inhibitor to inhibition of STAT3 mitochondrial transport and treatment of asthma. Specifically, the invention provides an application of an HSP90 inhibitor in preparation of a preparation for hindering STAT3 mitochondrial transport. The invention also provides an application of the HSP90 inhibitor in preparation of a preparation for inhibiting the function of the type 2 natural lymphoid cells. The invention also provides application of the HSP90 inhibitor in preparation of medicines for treating asthma or related diseases thereof. The invention also provides application of the STAT3 mitochondrial transport as a target spot in screening and / or preparing medicines for treating asthma or related diseases thereof.

Description

technical field [0001] The invention relates to a new application of an HSP90 inhibitor, specifically, the invention relates to a new application of an HSP90 inhibitor to hinder STAT3 mitochondrial transport and treat asthma, and belongs to the technical field of medicine. Background technique [0002] Asthma is a heterogeneous disease characterized by bronchial hyperresponsiveness, reversible airflow obstruction, and airway inflammation, manifested by recurrent episodes of wheezing, chest tightness, and coughing. It is one of the most common respiratory diseases worldwide, particularly in many developed countries, where it affects 5-10% of the population and is accompanied by a huge socioeconomic burden. Worldwide, asthma cases are increasing at a rate of about 50% per decade. According to the survey data of the World Health Organization, it is estimated that 300 million people worldwide suffer from asthma, and by 2025, there may be an increase of about 100 million people. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/395A61K31/7105A61P11/06A61P11/02A61P37/08A61P11/00
Inventor 郭晓欢付榴辉
Owner TSINGHUA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com